ADHD治疗,如何降低药物滥用风险?

2016-07-17 佚名 来宝网

一项新的研究结果显示,父母通常经常担心他们的孩子选择服用兴奋剂来治疗注意缺陷多动障碍(ADHD),他们认为这增加了物质滥用风险。目前,一项令人惊奇的新研究发现,当人们很早的服用或者长时间服用利他林和阿得拉药物时,药物滥用风险降低了。“最值得注意的是,对于那些很早开始服用,或服用兴奋剂类药物时间较长的ADHD青年人群来说,他们的药物滥用风险与普通人群是一样的,”该研究的负责人 Sean Esteba

一项新的研究结果显示,父母通常经常担心他们的孩子选择服用兴奋剂来治疗注意缺陷多动障碍(ADHD),他们认为这增加了物质滥用风险。

目前,一项令人惊奇的新研究发现,当人们很早的服用或者长时间服用利他林和阿得拉药物时,药物滥用风险降低了。

“最值得注意的是,对于那些很早开始服用,或服用兴奋剂类药物时间较长的ADHD青年人群来说,他们的药物滥用风险与普通人群是一样的,”该研究的负责人 Sean Esteban McCabe 表示。他是密歇根大学妇女和性别研究所的教授。

“研究发现,与那些早期发现(小于9岁)并长期用药(6年以上)的ADHD患者相比,那些后发病(15岁以上)并服用药物时间较短(2年以内)的ADHD患者,后者的药物滥用的风险是前者的两倍以上,” McCabe 表示。

在该项研究中,研究者们对40,000多名高中毕业生进行了研究,其中,服用处方兴奋剂的ADHD患者超过3500人,服用飞兴奋剂药物的患者约1,300人。

研究者们还对参与者的药物使用信息,以及青少年的酗酒、吸烟、使用大麻和可卡因历史进行了调研。

“用于治疗的中枢神经兴奋剂类药物对人体的反应存在延后效应,短的时间使用,以及使用非兴奋剂类药物的使用均与青春期程度的增加有关,” McCabe 表示。

但是研究人员表示,该研究并不能证明其中的因果关系。

研究者们表示,近年来,约八分之一的美国高中生使用兴奋剂或或非兴奋剂类药物治疗多动症。这些药物可以帮助患者缓解多动症的症状,例如:大脑紊乱,多动、冲动以及注意力缺乏等。
而新的研究则强调了:ADHD症状的药物治疗过程中,连续性、早期性的治疗十分重要。

“一些专家断言:ADHD的及早发现,以及适当的药物管理可能会降低ADHD的核心症状,如冲动,并可能会促进患病儿童的适应性行为,可以减少在以后生活中的药物使用和物质使用障碍,”他表示。

该研究相关文章发表于6月出版的《美国儿童和青少年精神病学会》(Journal of the American Academy of Child and Adolescent Psychiatry)杂志上。

原始出处:

McCabe SE, Dickinson K, West BT, Wilens TE.Age of Onset, Duration, and Type of Medication Therapy for Attention-Deficit/Hyperactivity Disorder and Substance Use During Adolescence: A Multi-Cohort National Study.J Am Acad Child Adolesc Psychiatry. 2016 Jun;55(6):479-86. doi: 10.1016/j.jaac.2016.03.011. Epub 2016 Apr 7.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1701521, encodeId=cf431e0152156, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Feb 27 21:30:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112794, encodeId=5397112e94c3, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 23:52:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95759, encodeId=a59495e5904, content=降低药物滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Aug 03 17:10:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307592, encodeId=9a4f130e59264, content=<a href='/topic/show?id=459f19e855' target=_blank style='color:#2F92EE;'>#ADHD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1978, encryptionId=459f19e855, topicName=ADHD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Tue Jul 19 11:30:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443226, encodeId=222914432264b, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Tue Jul 19 11:30:00 CST 2016, time=2016-07-19, status=1, ipAttribution=)]
    2017-02-27 zchen
  2. [GetPortalCommentsPageByObjectIdResponse(id=1701521, encodeId=cf431e0152156, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Feb 27 21:30:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112794, encodeId=5397112e94c3, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 23:52:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95759, encodeId=a59495e5904, content=降低药物滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Aug 03 17:10:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307592, encodeId=9a4f130e59264, content=<a href='/topic/show?id=459f19e855' target=_blank style='color:#2F92EE;'>#ADHD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1978, encryptionId=459f19e855, topicName=ADHD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Tue Jul 19 11:30:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443226, encodeId=222914432264b, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Tue Jul 19 11:30:00 CST 2016, time=2016-07-19, status=1, ipAttribution=)]
    2016-09-06 李东泽

    很好,不错,以后会多学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1701521, encodeId=cf431e0152156, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Feb 27 21:30:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112794, encodeId=5397112e94c3, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 23:52:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95759, encodeId=a59495e5904, content=降低药物滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Aug 03 17:10:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307592, encodeId=9a4f130e59264, content=<a href='/topic/show?id=459f19e855' target=_blank style='color:#2F92EE;'>#ADHD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1978, encryptionId=459f19e855, topicName=ADHD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Tue Jul 19 11:30:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443226, encodeId=222914432264b, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Tue Jul 19 11:30:00 CST 2016, time=2016-07-19, status=1, ipAttribution=)]
    2016-08-03 oo902

    降低药物滥用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1701521, encodeId=cf431e0152156, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Feb 27 21:30:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112794, encodeId=5397112e94c3, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 23:52:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95759, encodeId=a59495e5904, content=降低药物滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Aug 03 17:10:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307592, encodeId=9a4f130e59264, content=<a href='/topic/show?id=459f19e855' target=_blank style='color:#2F92EE;'>#ADHD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1978, encryptionId=459f19e855, topicName=ADHD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Tue Jul 19 11:30:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443226, encodeId=222914432264b, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Tue Jul 19 11:30:00 CST 2016, time=2016-07-19, status=1, ipAttribution=)]
    2016-07-19 lg.zhao
  5. [GetPortalCommentsPageByObjectIdResponse(id=1701521, encodeId=cf431e0152156, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Feb 27 21:30:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112794, encodeId=5397112e94c3, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 23:52:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95759, encodeId=a59495e5904, content=降低药物滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Aug 03 17:10:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307592, encodeId=9a4f130e59264, content=<a href='/topic/show?id=459f19e855' target=_blank style='color:#2F92EE;'>#ADHD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1978, encryptionId=459f19e855, topicName=ADHD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Tue Jul 19 11:30:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443226, encodeId=222914432264b, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Tue Jul 19 11:30:00 CST 2016, time=2016-07-19, status=1, ipAttribution=)]

相关资讯

Br J Psychiatry:ADHD兴奋剂治疗可降低物质使用障碍风险

《英国精神病学杂志》(The British Journal of Psychiatry)8月网络版刊登的一篇研究报告的结论显示,注意缺陷多动障碍(ADHD)的兴奋剂治疗或可降低物质使用障碍形成的风险,但对ADHD青少年尼古丁依赖的形成无影响。

Radiology:吸食兴奋剂,女性大脑灰质减少

一篇新的研究报告表明,女性长期滥用兴奋剂会影响其脑容量。即使长期服用拮抗药物后,脑组织相应的反馈、学习和执行功能也会发生巨大的变化。“我们发现,平均服用拮抗药物13.5个月后,既往显著依赖兴奋药物的女性相比健康女性而言,大脑一些区域的灰质体积明显减少,这些区域起到非常重要的作用,影响人决策的制定、情绪的变化、大脑反馈和习惯的形成。”本文作者Jody Tanabe博士,科罗拉多州大学丹佛医学院放射学

Lancet:震惊!健美运动员服用禁药后的可怕后果-案例报道

职业运动员使用性能增强药物得到越来越多的关注,这里将给大家带来一个关于业余健美运动员使用禁药后出现可怕后果的案例报道。患者男,21岁,因全身不适就诊。患者低热,在胸部和上背部有大量脓肿和脓疱,伴深溃疡。追问病史后,患者自诉有合成类固醇激素药物滥用史,每周服用两次250 mg庚酸睾丸素和30 mg去氢甲睾酮。患者诊断为:合成类固醇激素诱导的重度聚合型痤疮。治疗:停止合成类固醇激素的使用,使用防腐剂和

JAIDS:HIV感染者新希望,抗逆转录病毒治疗

近日旧金山加州大学新临床研究显示,与那些不使用兴奋剂的感染艾滋病毒的人相比,341名使用冰毒和可卡因的感染艾滋病毒的人通过抗逆转录病毒的方法治疗初步见效。 “艾滋病患者用抗逆转录病毒疗法常常遇到困难,部分原因由于医疗服务提供者的担忧,他们不能准确把握药物定向。来自本研究的发现表明,许多兴奋剂使用者能够准确把握抗逆转录病毒治疗方法,这样足以避免引起消极的临床后果。抗逆转录病毒疗法能引起一些较好

Pediatrics:兴奋剂治疗多动症或可降低患者吸烟风险

卡罗莱纳州达勒姆市——据杜克大学医学院研究人员领导的一份研究分析说,使用兴奋剂类药物治疗注意缺陷多动障碍(ADHD,简称多动症)或可降低吸烟风险,特别是在持续用药的情况下会有这样的效果。 《儿科》杂志网络版在2014年5月12日发表了这一研究成果。【原文下载】 “由于患有多动症的人更容易吸烟,我们的研究支持使用兴奋剂治疗以减少多动症青少年吸烟的可能性。”资深作家、杜克大学ADHD项目主

女性幼年期患注意缺陷多动障碍,则成年后肥胖风险大

在过去30年里,儿童和成人肥胖的发病率大幅上升,且有证据表明这与注意缺陷多动障碍(ADHD)明显相关。 既往研究已经表明,由于潜在的行为学、神经生物学和遗传机制等因素,ADHD和肥胖之间密切相关。 ADHD儿童易冲动和注意力不集中等行为因素会导致他们饮食不规律。 遗传和神经生物学因素可导致患儿多巴胺分泌系统或脑源性嗜神经因子(BDNF)分泌出现障碍。 既往研究指出,共同的病因学可能导致ADHD患儿